Company intelligence / Profile preview

BIOCURE

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

The company has reported strong clinical results for its CD19-targeted CAR-T program in acute lymphoblastic leukemia, with over 94% complete remission in preliminary studies; global pipeline includes biosimilars and CAR-T programs at Phase 1/IND stage, with pancreatic cancer and solid tumors in earlier development[1][5].

Therapeutic areas: OncologyNeurology
Modalities: CAR-T cell therapyBiosimilarInterferons
Industry: Biotech

Partnerships

Pharos Vaccine (R&D and clinical trials, China)Multiple joint ventures in Asia and EuropeInvestigator clinical trial partnerships with Beijing University Hospital (China)

Beyond the preview

Go deeper on BIOCURE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOCURE.

Explore the full profile